Amyotrophic Lateral Sclerosis: An Overview by Saudagar, Ravindranath & Garge, Lajri
Saudagar et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(3):613-616 
ISSN: 2250-1177                                                                                    [613]                                                                                    CODEN (USA): JDDTAO 
Available online on 15.05.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                               Review Article 
Amyotrophic Lateral Sclerosis: An Overview    
Saudagar Ravindranath1*, Garge Lajri2 
1 Department of Pharmaceutical Chemistry, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India 
2 Department of Pharmaceutical Quality Assurance, R.G. Sapkal College of Pharmacy, Anjaneri, Nashik-422213, Maharashtra, India 
 
ABSTRACT 
Amyotrophic Lateral Sclerosis is an adult-onset neurodegenerative disease that causes paralysis. Presently it is incurable and rapidly 
progressive with a survival of 4-5 years from onset. It is degeneration of upper and lower motor neurons which results in weakness and 
wasting of muscles in arms, legs, trunk and bulbar region. There are two types sporadic and familial amyotrophic lateral sclerosis. The age of 
onset of people with familial is widely reported as being about 10 years younger than for those with apparently sporadic amyotrophic lateral 
sclerosis. Epidemiological studies show a worldwide incidence of 2-3 per year per 100-000 population over age of 15 years. About 10% of 
individuals have a family history of amyotrophic lateral sclerosis. The cause is unknown. Genes linked to diseases have been identified including 
one (C9ORF72) that seems to be particulary important. Researchers are studying several causes of ALS like gene mutation, chemical imbalance, 
disorganized immune response and protein mishandling. Riluzole and Radicava were approved for the treatment by the Food and Drug 
administration. The diagnosis of ALS is devastating for patient and family members. People with ALS should be delivered with multidisciplinary 
team. The current hope is that stem cells of neural or extraneural origin might be modified in vitro to neurons that may migrate to the sites of 
motor neuron loss. The quality of life is important not just the duration of survival.  
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INTRODUCTION   
Amyotrophic Lateral Sclerosis (ALS) is an adult-onset 
neurodegenerative disease that leads to paralysis. Presently 
it is incurable and rapidly progressive with a mean survival 
of 4–5 y from onset.1 Amyotrophic lateral sclerosis or motor 
neuron disease in its purest form is a readily identified 
clinical condition. It is rapidly progressive degeneration of 
upper and lower motor neurons, which results in weakness 
and wasting of muscle in the arms, leg, trunk and bulbar 
region. Amyotrophic lateral sclerosis which is one of the 
most common motor neuron degenerative diseases typically 
attacks adults during midlife. Although ALS cases have been 
detected all over the world interestingly the prevalence of 
the geographic location of the Western Pacific form of ALS is 
50–100 times higher than elsewhere world. One of the first 
studies performed in this population in 1957 described a 
genetic origin of ALS associated with Parkinsonism and 
dementia independent of environmental changes. However 
recent studies have noted a decreased incidence in these 
areas over the past 40 years.2 A combination of upper and 
lower motor neurone dysfunction was named amyotrophic 
lateral sclerosis (ALS) by Charcot and Joffroy. In the united 
states ALS or Lou Gehrig’s disease are terms used to describe 
all forms of the disease where the combination of upper and 
lower motor neurone involvement. It is the third commonest 
neurodegenerative disease after Alzheimer’s and Parkinson’s 
diseases. Despite its rarity the disease has gain a lot of 
attention as its devastating course places it at the centre of 
the ethical dispute about end of life decision making and 
physician assisted suicide.3 
TYPES  
Sporadic and Familial Als  
There is arresting heterogeneity in the genetic causes of 
familial amyotrophic lateral sclerosis but familial and 
sporadic amyotrophic lateral sclerosis have similarities in 
their pathological features and in their clinical features 
suggesting a convergence of the cellular and molecular 
events that lead to motor neuron degeneration. 5 The age of 
onset of people with familial Amyotrophic lateral sclerosis is 
widely reported as being about 10 years younger than for 
those with apparently sporadic amyotrophic lateral 
sclerosis.6 
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PATHOGENESIS 
1. Background Vulnerability 
Epidemiological studies of ALS show a worldwide incidence 
of 2–3 per year per 100 000 population over the age of 15 
year and an overall lifetime risk of developing amyotrophic 
lateral sclerosis of 1:350 for men and 1:400 for women. An 
outward increase in incidence in the disorder in the last few 
decades may be due to improved diagnosis an aging 
population or a genuine increase the frequency of the 
disease. Around 10% of individuals have a family history of 
ALS. A study of twin data suggested that heritability 
contributes 60% to the risk of developing amyotrophic 
lateral sclerosis and environment 40% but an analysis from 
three genome-wide association studies found a lower 
heritability of 21%.8 
2. Genes 
Although the majority of amyotrophic lateral sclerosis cases 
are sporadic in the past 2 decades mutations identified in 
several genes have provided insight into potential disease 
mechanisms and presented opportunities for disease 
modelling. The brief introduction of some of the most 
commonly studied mutations as well as some recently 
identified that are relevant to our current understanding of 
pathogenesis. An increasing number of genes are recognized 
as associated and causative of amyotrophic lateral sclerosis. 
The most common are C9orf72, SOD1, TARDBP and FUS.8-10 
C9ORF72 
C9orf72 is the most frequent genetic change identified in 
patients with amyotrophic lateral sclerosis. Expansions are 
found in around 39% of familial ALS patients and 7% of 
apparently sporadic cases of European ancestry but with 
significant differences between populations. For example 
study of 563 patients with ALS in japan identified expansions 
in 0.4% of sporadic and 0% of familial ALS patients and in 
less than 1% of chinese sporadic ALS patients. Patients with 
ALS often display cognitive changes with features of apathy, 
disinhibition, socially inappropriate behaviour, abnormal 
eating behaviours, loss of empathy and stereotyped or 
obsessive-compulsive behaviour. Hallucinations and 
delusions may occur. Within a family some individuals may 
have amyotrophic lateral sclerosis. The genetic feature is 
hexanucleotide repeat of GGGGCC either in the promotor or 
intron 1 of the gene. The normal range of repeats is uncertain 
but usually considered up to 20 repeats while patients with 
ALS usually have repeats of several hundred to thousands. 
Inheritance is autosomal dominant. There is no clear 
intergenerational anticipation however short expansions 45-
78 repeats have been associated with age at onset and 
C9ORF72 families displayed possible anticipation. There is 
TDP-43 pathology. There are also p62-positive neuronal 
cytoplasmic inclusions composed of dipeptide repeat 
proteins (DPR) formed by translation from the abnormally 
expanded repeat in C9ORF72. A particular feature of the 
C9ORF72 expansion is repeat-associated non- ATG (RAN) 
translation that can occur in all six sense and antisense 
frames resulting in five different DPR proteins. The 
mechanisms of toxicity remain unclear but a richer 
understanding is gradually being achieved.8 
SOD1 
Copper zinc superoxide dismutase (SOD1) was the first 
genetic cause of amyotrophic lateral sclerosis to be identified 
in 1993. Mutations are commonly estimated to be present in 
around 20% of familial patients and 1% of apparently 
sporadic. The frequency will vary between populations and 
in an Italian population SOD1 mutations were identified in 
14% of familial amyotrophic lateral sclerosis patients.7 
Founder haplotypes may have significant effects on 
frequency. The mutations are predominantly point 
mutations. Inheritance is autosomal dominant. There are 
over 170 different genetic alterations recognized although 
many of these are private to individuals and causation may 
be difficult to prove outside large families. Disease 
pathogenesis remains uncertain but an unusual feature is the 
absence of TDP-43 pathology now supposed to be typical of 
ALS otherwise. The disease mechanism appears to be a gain 
of function and not a loss of enzyme function. Protein 
misfolding and oxidative stress are amongst the possible 
mechanism.8 
TARDBP  
TAR DNA-binding protein 43 (TARDBP/TDP-43) mutations 
are found in around 5% of patients with familial 
amyotrophic lateral sclerosis. Inheritance is autosomal 
dominant. TDP-43 is the protein typically found in the tau 
and alpha-synuclein-negative, ubiquinated, cytoplasmic 
inclusions or aggregates found in amyotrophic lateral 
sclerosis and a subset of FTD. TDP-43 is an RNA and DNA 
binding protein that regulates transcription, mRNA splicing, 
transport and stability.8 Current pathogenic include a gain of 
function toxicity of mutant TDP-43 in disruption of stress 
granules that aggregate and form cytoplasmic ubiqutinated 
protein inclusions. Loss of function may occur through 
depletion of TDP-43 in the nucleus of the motor neuron 
when the TDP-43 is included in the cytoplasmic 
ubiquitinated protein inclusions induced by mutant TARDBP 
it resulting in dysregulation of nuclear RNA metabolism.9 
FUS  
Fused in sarcoma translated in liposarcoma (FUS) is also 
found in around 5% of patients with familial amyotrophic 
lateral sclerosis.(8) FUS is a nucleoprotein that regulates RNA 
and DNA binding, gene expression and mRNA splicing. FUS 
colocalises with TDP-43 to stress granules in the motor 
neuron. Potential pathogenic mechanisms are similar to 
those of TDP-43.9 
SYMPTOMS 
The symptoms of ALS usually appear when a person is in 
their after 50s or before 60s but it can happen at other ages. 
Progression varies between individuals. In the early stages 
the symptoms may be barely noticeable but the weakness 
becomes more visible over time. 
Early symptoms and signs include: 
1. Difficulty carrying out daily activities including 
walking. 
2. Increased clumsiness. 
3. Weakness in the feet, hands, legs and ankles. 
4. Cramping and twitching in the arms, shoulders and 
tongue. 
5. Difficulty in sustaining the good posture and holding 
the head up. 
6. Uncontrolled outbursts of laughing or crying 
(emotional liability). 
7. Cognitive changes. 
8. Slurring of speech and struggle with voice projection. 
9. Pain. 
10. Fatigue. 
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11. Problems with saliva and mucus. 
12. Difficulty in breathing and swallowing in the later 
stages. 
Researchers are studying the several possible causes of 
amyotrophic lateral sclerosis including: 
1. Gene Mutation 
Several genetic mutations can lead to inherited amyotrophic 
lateral sclerosis which causes nearly the similar symptoms as 
the noninherited form.   
2. Chemical Imbalance 
People with amyotrophic lateral sclerosis usually have 
higher than normal levels of glutamate a chemical messenger 
in the brain around the nerve cells in their spinal fluid. Too 
much glutamate is known to be toxic to several nerve cells. 
3. Disorganized Immune Response 
Sometimes a person's immune system begins attacking some 
of his or her body's specific normal cells which may lead to 
the death of nerve cells. 
4. Protein Mishandling  
Mishandled proteins within the nerve cells may lead to a 
gradual accumulation of abnormal forms of these proteins in 
the cells destroying the nerve cells. 
Progressive muscle weakness occurs in all cases of 
amyotrophic lateral sclerosis but this may not be the first 
indication of the condition. Early symptoms often include 
clumsiness, abnormal limb fatigue, muscle cramps and 
twitches and slurred speech. Symptoms will spread to all 
portions of the body as amyotrophic lateral sclerosis 
progresses. Some people may have difficulties with decision 
making and memory eventually leading to a form of 
dementia called frontotemporal dementia. Emotional lability 
can cause instabilities in mood and emotional response.13 
DIAGNOSIS 
It is not widely appreciated outside of specialist clinics that 
there are a number of symptoms associated with motor 
neuron diseases which are highly amenable to treatment. 
The aim of these interventions is primarily palliative and 
aimed at maintaining quality of life rather than to prolong 
the duration of illness.3 Riluzole drug was approved for ALS 
treatment by the Food and Drug Administration (FDA) in 
1995 and it appears to slow the progression of the disease. In 
May 2017 Radicava (Edaravone) was approved to treat ALS. 
The most significant benefit of riluzole is observed after 
intervention in the early stages of the disease. Thus an early 
diagnosis of ALS could provide the most effective results. 
Since diagnosis of ALS relies on clinical symptoms and the 
time from the first symptoms to diagnosis is about 12 
months there is a delay hindering a successful therapy. This 
phenomenon underlies the importance of the development 
of screening tests able to detect the disease in early stages. 
The diagnosis of amyotrophic lateral sclerosis is devastating 
for the patient and family members and must be handled 
sensitively. Scheduling a follow up appointment soon after 
diagnosis is beneficial to answer questions not dealt with 
during the initial consultation and can help provide further 
information about support networks which are well 
established in most developed nations.11 
Tests that may help diagnose amyotrophic lateral sclerosis 
are:           
I. Electromyography (EMG) which identifies electrical energy 
in muscles 
II. Nerve conduction study (NCS) which tests how well the 
nerves direct signals. 
THERAPY 
Physical therapy : 
It can help people with ALS achieve pain and report mobility 
issues. A physical therapist can provide help and information 
with: 
a. Low-impact exercises to enhance cardiovascular fitness 
and overall well-being. 
b. Mobility aids such as walkers and wheelchairs. 
c. Devices to make life simple such as ramps. 
Occupational therapy : 
 It can help a patient to keep their independence for longer 
by: 
a. Helping patients select adaptive equipment and 
assistive technologies to help them keep up their daily 
routines.                       
b. Train them in ways to compensate for hand and arm 
weaknesses. 
Breathing therapy : 
It is required in time as the respiratory muscles get weaker. 
Breathing devices can support the patient breathe better at 
night. Some patients may need mechanical ventilation. One 
end of a tube is attached to a respirator while the other end 
is inserted into the windpipe through a surgically-created 
hole in the neck or tracheostomy 
Speech therapy : 
It is useful when ALS begins to make it harder to talk. Speech 
therapists can help by teaching adaptive techniques. Other 
methods of communication include writing and computer 
based communications equipment. 
Nutritional support : 
It is important as struggle with swallowing can make it hard 
to get enough nutrients. Nutritionists can advise on 
preparing nutritious meals that are easier to swallow. 
Suction devices and feeding tubes may help.13 
MANAGEMENT 
People with MND and their carers have complex needs which 
can only adequately be delivered by a multidisciplinary team 
experienced in the management of progressive neurological 
disability. This should routinely include a physiotherapist to 
advise on mobility, postural support and prevention of 
contractures a speech and language therapist to assess 
swallowing and provide communication aids an occupational 
therapist to provide aids to maintain function (wheelchair, 
mobile armsupports, etc) a dietitian to advise on maintaining 
weight and percutaneous endoscopic gastrostomy feeding. 
Symptomatic treatments remain the cornerstone of 
management for patients with ALS. For some patients these 
treatments not only alleviate symptoms but also improve 
survival and quality of life. Multidisciplinary models of care 
have developed as a predictor of survival reducing the risk of 
death by 45% at 5 years. Compared with patients managed 
in a general neurology clinic patients managed in a 
specialised clinic had a better quality of life possibly 
attributable to more effective use of resources, with benefits 
derived after a single visit.12,13 
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FUTURE PROSPECTS 
Although described in the mid-19th century amyotrophic 
lateral sclerosis has proved to be one of the most puzzling 
neurodegenerative diseases and remains largely untreatable. 
Much of our knowledge of the pathogenesis of Amyotrophic 
lateral sclerosis comes initially from analysis of postmortem 
material in which the disease process is advanced and many 
of the changes reflect the end stage of a cascade of metabolic 
derangements resulting in motor neurone degeneration. 
Despite the intense research activity of the last y the use of 
miRNAs as biomarkers for diagnosis of amyotrophic lateral 
sclerosis and clinical management of patients is still in an 
early stage of development. Several interesting data have 
been obtained so far with important insights into the disease 
processes. At the same time when possible future studies 
should try to combine data obtained from multiple source of 
sample (blood, CSF and muscle) of the same patient. Up to 
date only few studies have performed this kind of analysis 
and their results are quite conflicting.The ultimate objective 
is to include these biomarkers in all phases of Amyotrophic 
lateral sclerosis management from the diagnosis to the 
clinical trials and in perspective to the identification of future 
therapeutic approaches.11 The recent hope is that stem cells 
of neural or extraneural origin might be changed in vitro to 
differentiate into neurones that would migrate to sites of 
motor neurone loss and form functional networks to restore 
the motor pathways lost in motor neuron diseases. It is 
important that quality of life not just duration of survival is 
part of the measure of effectiveness of drug regimens.13 
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